Company intelligence / Profile preview

MValve Technologies

Ownership: Private
Development stage: Phase 1

Overview

MValve Technologies is developing a minimally invasive transcatheter mitral valve replacement system designed to work with Boston Scientific’s Lotus Valve. The approach allows repositioning and recapture for precise placement. As of the last available updates, funding was being used to support first-in-human trials targeting patients with mitral regurgitation. No published pivotal or late-stage results are available.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Drug pipeline

1 asset

MValve docking system

Phase 1

Indications: Mitral regurgitation

Partnerships

Boston Scientific (lead investor and strategic partner; exclusive acquisition option)

Beyond the preview

Go deeper on MValve Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MValve Technologies.

Explore the full profile